Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    130
    ...
ATC Name B/G Ingredients Dosage Form Price
N07BC01 BUPRENORPHINE ARROW G Buprenorphine - 8mg 8mg Tablet 1,115,389 L.L
N07BC01 BUPRENORPHINE ARROW G Buprenorphine - 2mg 2mg Tablet 563,070 L.L
C09AA01 ORBACE G Captopril - 25mg 25mg Tablet 522,179 L.L
J01AA02 FARMODOXI G Doxycycline (hyclate) - 100mg 100mg Tablet 310,428 L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 2mg 2mg Tablet 931,283 L.L
C01DA08 ISDN G Isosorbide dinitrate - 10mg 10mg Tablet 311,771 L.L
C09AA01 ORBACE G Captopril - 50mg 50mg Tablet 949,649 L.L
G03DB08 VISANNE B Dienogest - 2mg 2mg Tablet 4,980,280 L.L
C01DA08 ISODEX G Isosorbide dinitrate - 10mg 10mg Tablet 138,224 L.L
C09AA02 RENITEC B Enalapril maleate - 20mg 20mg Tablet 405,840 L.L
C10AA01 ZOCOR B Simvastatin - 10mg 10mg Tablet 881,817 L.L
G03DB08 DIENOSIS G Dienogest - 2mg 2mg Tablet 2,822,069 L.L
C09AA03 ZESTRIL B Lisinopril (dihydrate) - 5mg 5mg Tablet 295,645 L.L
G03DC02 PRIMOLUT NOR B Norethisterone acetate - 5mg 5mg Tablet 296,989 L.L
C09AA03 TENSIKEY G Lisinopril - 5mg 5mg Tablet 456,906 L.L
C10AA01 STAVINE G Simvastatin - 10mg 10mg Tablet 207,336 L.L
G03FB01 PROGYLUTON B Norgestrel - 0.5mg (tablet 2), Estradiol valerate - 2mg (tablet 1, tablet 2) Tablet 193,513 L.L
M04AC01 COLCHICINE SEID G Colchicine - 1mg 1mg Tablet 382,995 L.L
C09AA03 ZESTRIL B Lisinopril (dihydrate) - 10mg 10mg Tablet 592,635 L.L
M05BA04 FOSAMAX 70MG ONCE WEEKLY B Alendronate - 70mg 70mg Tablet 1,988,887 L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 4mg 4mg Tablet 1,276,650 L.L
C09AA03 ZESTRIL B Lisinopril (dihydrate) - 20mg 20mg Tablet 636,981 L.L
C10AA01 ZOCOR B Simvastatin - 20mg 20mg Tablet 976,526 L.L
M05BA04 APO-ALENDRONATE G Alendronate (monosodium trihydrate) - 70mg 70mg Tablet 981,005 L.L
C01DX12 CORVASAL 4MG B Molsidomine - 4mg 4mg Tablet 492,742 L.L
C09AA03 TENSIKEY G Lisinopril - 20mg 20mg Tablet 460,938 L.L
C01DX12 MOLSIDOMINE BIOGARAN G Molsidomine - 4mg 4mg Tablet 344,024 L.L
N07CA01 BETASERC B Betahistine dihydrochloride - 16mg 16mg Tablet 1,623,708 L.L
C10AA01 STAVINE G Simvastatin - 20mg 20mg Tablet 207,336 L.L
M05BA04 STRONDEX 70 G Alendronate sodium - 70mg 70mg Tablet 1,305,447 L.L
    ...
    130
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025